Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

f being prepared to launch Acetavance at the earliest possible date following approval."

Financial Results

For the three months ended June 30, 2009, Cadence reported a net loss of $8.3 million, or $0.17 per share, compared to a net loss of $15.6 million, or $0.41 per share, for the same period in 2008. For the six months ended June 30, 2009, Cadence reported a net loss of $18.7 million, or $0.40 per share, compared to a net loss of $29.3 million, or $0.83 per share, for the same period in 2008. The per share amount for the three and six month periods of 2009 includes the effect of the issuance of 12,039,794 shares of common stock during the first quarter of 2009 pursuant to a private placement transaction and the issuance of 9,240,307 shares of common stock pursuant to a registered direct offering of common stock during the first quarter of 2008. The per share amounts for three and six month periods of 2008 include only the effect of the 2008 common stock issuance.

Operating expenses for the three months ended June 30, 2009 were $8.0 million, a decrease of $7.6 million from the $15.6 million reported for the comparable period in 2008. Operating expenses for the six months ended June 30, 2009 were $18.1 million, a decrease of $11.2 million from the $29.3 million reported for the comparable period in 2008. The decreases in the current year expenses are primarily due to a reduction in research and development costs as the company completed its clinical development program for Acetavance in early 2009 and submitted an NDA for this product candidate in May 2009. Further, in March 2009, Cadence discontinued the development program for its omiganan product candidate and has incurred a limited amount of expense thus far during the year as it completes the regulatory requirements for this program.

As of June 30, 2009, Cadence held cash and cash equivalents of $105.4 million, which includes proc
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
3. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 MabVax Therapeutics ... company announces that the Company,s lead antibody, HuMab 5B1, ... five separate presentations during the upcoming World Molecular Imaging ... September 2-5, 2015. Researchers from the Department of ... present results on the use of MabVax,s lead antibody ...
(Date:8/31/2015)... Aug. 31, 2015  For people with Down syndrome, ... day. The biotechnology company, located in the Science + ... the best potential therapies yet for people with Down syndrome ... Correction of Down syndrome and Edwards syndrome aneuploidies in ... DNA Research . Elixirgen plans to develop this technology ...
(Date:8/31/2015)... , Aug. 31, 2015 FLX Bio, ... development of novel cancer immunotherapies, announced today that it ... Chief Executive Officer and William Ho , M.D., ... join an experienced management team led by veterans of ... , Ph.D., Chief Scientific Officer; Jay Powers , ...
(Date:8/31/2015)... ... ... There’s a new treatment option for excessive menstrual bleeding – The Minerva ... system in the last 14 years, and the only endometrial ablation product to combine ... 66%, the high Patient Satisfaction rate of 98%, and the fastest procedure time (3 ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4New Down syndrome therapy discovered 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... BEIJING and CLAREMONT, Calif., Jan. 17 /Xinhua-PRNewswire-FirstCall/ ... completed its annual,management meetings including yearend business ... The meetings commenced in,Xiaotangshan, Beijing on January ... managers and staff from Kiwa,s corporate,headquarters in ...
... Andy, Holder Completes First Year Inspiring Others to Manage Chronic ... ... In 2007, Good Neighbor,Pharmacy(R) featuring Diabetes Shoppe(R), teamed up with "Iron Andy" ... to speak about living with diabetes as an Ironman competitor, but,his message ...
... Healthcare, a,division of Wyeth (NYSE: WYE ), supports ... longer recommend use of,over-the-counter cough and cold products in ... with our voluntary removal in October 2007,of over-the-counter infant ... reduce dosing errors and overdoses in children who are ...
Cached Biology Technology:Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 2Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 3Good Neighbor Pharmacy(R) Ironman Competitor Inspires Individuals with Diabetes to Live Without Limits 2Good Neighbor Pharmacy(R) Ironman Competitor Inspires Individuals with Diabetes to Live Without Limits 3Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age 2Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age 3
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s ... in 2015 that relate to sales of FPC1155 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... smartphone manufacturer in China and we are ... for Z1 , its ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the second ... Second quarter contract revenue of $ 85.2 million, ... margins of 26 % , Second quarter ... from royalties in the current quarter , Operating ... pleased to present another strong financial quarter, with all our divisions ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... By investigating the interplay between pheromone signaling and behavior ... an adult fly's earlier experience as a young individual ... adult. In particular, the researchers found that pheromone signals ... influence how young flies will behave once they reach ...
... specifically its active ingredient, tetrahydrocannabinol--has a well-documented ... have traced this property to cannabinoid receptors ... understanding of the neural circuitry underlying this ... practical implications because blocking the cannabinoid receptor, ...
... Northwestern University researchers have demonstrated how the microenvironments ... (federally approved) induced metastatic melanoma cells to revert ... ability to form colonies similar to hESCs. The ... less invasive following culture on the microenvironments of ...
Cached Biology News:Past experience of pheromones induces dominant courtship behavior in fruit flies 2Machinery of the 'marijuana munchies' 2Stem cell microenvironment reverses malignant melanoma 2
...
... Normal;heading 1;heading 2;Many ... and experimental situations ... standard transfection and ... systems. ViraPower Lentiviral ...
LTBP-2 (7B10)...
... Rabbit polyclonal to Kv4.2 Immunogen ... corresponding to amino acids 23-43 of Rat ... with Rat.Expected to cross-react with Human (100% ... immunogen), Rabbit (100% identity with immunogen) and ...
Biology Products: